
|Videos|June 25, 2021
Dr. Motzer on HRQOL with pembrolizumab plus lenvatinib in advanced RCC
Author(s)Urology Times staff
Advertisement
Robert J. Motzer, MD, discusses health-related quality of life (HRQOL) analyses from the phase 3 CLEAR trial of frontline pembrolizumab (Keytruda) plus lenvatinib (Lenvima) in patients with metastatic renal cell carcinoma (RCC). According to Motzer, the results showed that the combination resulted in similar HRQOL outcomes and disease-related symptom scores as single-agent sunitinib (Sutent). Motzer is the Kidney Cancer Section Head, Genitourinary Oncology Service; and Jack and Dorothy Byrne Chair in Clinical Oncology at Memorial Sloan Kettering Cancer Center.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Datopotamab deruxtecan enters phase 3 trial in high-risk muscle-invasive urothelial cancer
2
Pearls & Perspectives: From Emergency Medicine to Sexual Medicine, With Jeff Myers, DO
3
Nicole L. Miller, MD, FACS, on persistent LUTS after BPH treatment
4
AI system links surgical gestures with postoperative outcomes
5












